Compare ALIT & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALIT | QTTB |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.4M | 450.1M |
| IPO Year | 2020 | 2018 |
| Metric | ALIT | QTTB |
|---|---|---|
| Price | $8.95 | $8.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $17.00 | ★ $42.25 |
| AVG Volume (30 Days) | 399.1K | ★ 605.5K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | ★ 8.97% | N/A |
| EPS Growth | N/A | ★ 136.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,262,000,000.00 | $53,737,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $150.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $1.91 |
| 52 Week High | $23.68 | $23.57 |
| Indicator | ALIT | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 28.18 | 24.42 |
| Support Level | $0.56 | $5.12 |
| Resistance Level | $15.32 | $16.85 |
| Average True Range (ATR) | 0.75 | 0.68 |
| MACD | -0.31 | -0.13 |
| Stochastic Oscillator | 1.15 | 5.86 |
Alight Inc is a technology-enabled services company delivering human capital management solutions to many complex organizations. This includes the implementation and administration of employee benefits (e.g., health, wealth, and leave benefits) solutions, which currently operate under one reportable segment, Employer Solutions. The Employer Solutions segment is driven by the Alight Worklife platform, and includes integrated benefits administration, healthcare navigation, financial well-being, leave of absence management, and retiree healthcare. Geographically, the company generates the majority of its revenue from the United States.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).